Naltrexone is a front-line treatment for alcohol use disorders, but its efficacy is limited by poor medication adherence. This randomized controlled trial evaluated whether a mobile health intervention could improve naltrexone adherence.
Treatment-seeking participants with an alcohol use disorder (N = 76) were randomized to intervention and control conditions. All participants received naltrexone (50 mg/day) with a medication event monitoring system (MEMS) and a prepaid smartphone, and received a daily text message querying medication side effects, alcohol use, and craving. Those in the intervention arm received additional medication reminders and adherence assessment via text message.
The primary outcome, proportion of participants with adequate adherence (defined as ≥80% of prescribed doses taken through Week 8), did not differ between groups in intent-to-treat analyses (p = .34). Mean adherence at study midpoint (Week 4) was 83% in the intervention condition and 77% in the control condition (p = .35). Survival analysis found that the intervention group sustained adequate adherence significantly longer (M = 19 days [95% CI = 0.0–44.0]) than those in the control group (M = 3 days [95% CI = 0.0–8.1]) during the first month of treatment (p = .04). Medication adherence did not predict drinking outcomes.
These results suggest that in the context of daily monitoring and assessment via cell phone, additional text message reminders do not further improve medication adherence. Although this initial trial does not provide support for the efficacy of text messaging to improve adherence to pharmacotherapy for alcohol use disorders, additional trials with larger samples and alternate designs are warranted.
Citation: Stoner SA, Arenella PB, Hendershot CS (2015) Randomized Controlled Trial of a Mobile Phone Intervention for Improving Adherence to Naltrexone for Alcohol Use Disorders. PLoS ONE 10(4): e0124613. https://doi.org/10.1371/journal.pone.0124613
Academic Editor: Javier R. Lama, Asociacion Civil Impacta Salud y Educacion, PERU
Received: January 1, 2015; Accepted: February 28, 2015; Published: April 24, 2015
Copyright: © 2015 Stoner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: These data are publicly available at: http://dx.doi.org/10.6084/m9.figshare.1316613.
Funding: This research was supported by a Small Business Innovation Research contract # HHSN275201000011C from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to Talaria, Inc. (Principal Investigator, Dr. Stoner). NIAAA had no role in the design, conduct, or reporting of this study. Talaria, Inc., has closed and donated its technology to the Alcohol and Drug Abuse Institute at the University of Washington. Drs. Stoner, Arenella, and Hendershot report no financial relationships with commercial interests. Neither the funders nor the owners of Talaria, Inc., had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: All authors report no conflicts of interest and no financial relationships with commercial interests. The development and evaluation of the mHealth intervention described in this manuscript were wholly funded by a Small Business Innovation Research Phase II contract from the National Institute on Alcohol Abuse and Alcoholism to Talaria, Inc., a small business in Seattle, WA (Principal Investigator: Dr. Susan Stoner). Talaria, Inc., did not provide any of its own funds for the study described in this manuscript. Neither the funders nor the owners of Talaria, Inc., had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Talaria, Inc., went out of business in June 2014 and donated its products and web-based content authorship platform to the Alcohol and Drug Abuse Institute at the University of Washington, with which Dr. Stoner is now affiliated. This does not alter our adherence to all PLOS ONE policies on sharing data and materials.
Medication nonadherence is a significant barrier to the pharmacological treatment of alcohol use disorders [1–3]. Naltrexone, one of few approved medications for the treatment of alcohol dependence, delays relapse to heavy drinking, reduces number of heavy drinking days, and increases number of days abstinent [4–6]. Naltrexone is not highly utilized, however, in part due to concerns about non-adherence . It is well recognized that the efficacy of naltrexone is contingent on high adherence [8–11]. For example, effects of naltrexone versus placebo may only be evident only among patients with high adherence [8,11,12], and treatment outcomes correlate with adherence rates [13–16]. Adequate naltrexone adherence has been defined as taking at least 80% of prescribed doses [12, 13, 16]. Naltrexone adherence is generally suboptimal over 12–16 weeks [10,11,13–15,17,18] and worse over longer periods . Marginal adherence compromises treatment effectiveness in real-world settings and the ability to detect medication effects in randomized trials [1,5,8,19].
Randomized trials of naltrexone have included medication monitoring and behavioral interventions to support adherence [5,15,21] but these interventions have rarely been evaluated experimentally . Although behavioral interventions [10,22,23] appear to be beneficial [4,10], adherence remains suboptimal in clinical trials  and is likely far poorer outside the research context [1,24], suggesting the need for innovative, low-cost interventions to improve medication adherence in both clinical and research contexts . Notably, evidence suggests that more rigorous adherence monitoring is associated with greater medication effects , suggesting that monitoring alone could improve adherence.
A number of Internet-based interventions have been developed to address medication adherence for variety of conditions. A review of 13 studies noted that, although some have shown efficacy, only one study used a high-quality measure of adherence . Some form of monitoring was a key component in several of these interventions, and while a few used mobile self-monitoring devices, none used the most ubiquitous and convenient device currently available: the mobile phone. Because mobile phones offer a high degree of access to individuals in their daily lives, they are well suited for just-in-time intervention delivery [27,28].
Initial mobile health (mHealth) interventions for improving medication adherence [29,30] have used text message medication reminders, functioning essentially as an alarm clock. In contrast, the present study incorporated a recently developed platform for mobile, web-based adherence reminders that matches intervention intensity to adherence performance, while also assessing self-reported adherence on an ongoing basis. This low-cost, low-resource, easily scalable mHealth intervention, delivered via smartphone, integrates text message reminders and mobile web-based adherence assessment. The present study is a randomized, controlled trial to evaluate its feasibility and efficacy for improving naltrexone adherence in a treatment-seeking sample . We hypothesized that, compared to a control condition involving mobile self-report of side effects, drinking, and craving, the addition of adaptive mobile medication reminders and adherence assessments would be associated with better adherence, which in turn would be associated with better treatment outcomes.
Materials and Methods
Participants (N = 76) were 21–55 years old. Inclusion criteria included a) average weekly consumption of ≥14 (women) or ≥21 (men) standard drinks over the past 3 months; b) ≥2 heavy drinking days (≥4 [women] or ≥5 [men] standard drinks) in a 30-day period within the prior 90 days; c) desired assistance to reduce or stop drinking alcohol; and d) willingness to take naltrexone. Individuals were excluded for likelihood of pregnancy; opioid use or drug use other than alcohol, nicotine, or cannabis in the prior 30 days; history of opioid dependence or psychotic disorder; use of psychiatric medication other than antidepressants; concurrent treatment for alcohol use other than Alcoholics Anonymous; or a requirement to attend treatment.
The study protocol was reviewed and approved by the University of New Mexico Human Research Review Committee and Quorum Review (Seattle, WA), ClinicalTrials.gov Identifier: NCT01349985.
Recruitment and Screening.
Participants were recruited using newspaper, radio, and online advertisements in the Albuquerque, New Mexico area between August 2011 and November 2012. Advertisements stated that researchers were seeking participants who wished to cut down or quit drinking for involvement in a medication study. Those passing a phone screen were scheduled for further in-clinic screening, at which the study was fully described, any questions were answered, and written informed consent was obtained before continuing. Participants then completed a demographics questionnaire, urine drug toxicology and pregnancy screening, and a blood draw. Participants also completed an interview assessment that included a structured diagnostic interview; all participants met criteria for a current (past year) alcohol use disorder (alcohol abuse or alcohol dependence). The study psychiatrist reviewed blood work results and approved those within acceptable limits. Participants were asked to abstain from alcohol for 72 hours prior to their scheduled baseline appointment to facilitate a clinical assessment of withdrawal symptoms using the Clinical Institute Withdrawal Assessment (CIWA-Ar) protocol. A CIWA score of ≥8 was an additional exclusion criterion. Fig 1 illustrates participant recruitment and flow through the study.
Participants completed additional baseline questionnaires, after which random assignment to parallel conditions, either the intervention (n = 37) or control (n = 39), occurred 1:1 via a computerized algorithm that balanced groups according to self-reported drinking goal (to moderate or to abstain). Random allocation sequences had been generated in blocks of 8 by computer algorithm before the study began. To conceal the allocation sequence from study personnel, the process was computer-automated. The experimenter was notified via text message (SMS) from the computer of each random assignment as it occurred. Given that the efficacy of naltrexone has been demonstrated and this study examined adherence as the primary outcome, there was no placebo condition.
Randomized participants were provided with an initial one-month supply of naltrexone (50mg/day) and an Android smartphone with 8 weeks of unlimited service. Participants were instructed on using the phone to respond to question prompts. All were told to expect daily questions about side effects, alcohol use, and alcohol craving, with the additional possibility of text message reminders and assessments of naltrexone adherence. Participants were instructed to bring their medication bottle upon their return to the clinic at Weeks 4 and 8.
In-clinic assessments at Weeks 4 and 8 included an assessment of side effects and past 30-day alcohol use, a blood draw, and a physician follow-up assessment. Any smartphone-related problems were addressed. Those medically approved to continue received a medication refill. Participants were compensated at each visit and allowed to keep the study smartphone. No changes were made to the methods or primary outcomes after the trial commenced. At Week 8, those interested in continuing naltrexone received referrals. Additional study protocol details have been reported previously .
The intervention was called AGATE-Rx (Adaptive, Goal-directed Adherence Tracking and Enhancement). Its design and development is described elsewhere . In brief, AGATE reminded participants to take the study medication via SMS text messages. Additionally, a hyperlink in the message launched the web browser to assess adherence. Over time, the frequency of medication reminders was adapted according to self-reported adherence performance (see supplemental material for details). In addition to the AGATE-Rx adherence reminders/assessments, participants in the intervention condition received a Smartphone Alcohol and Side Effects Diary (SASED), consisting of daily SMS prompts with hyperlinks to assess side effects and alcohol use and craving. Screenshots from the intervention and content of all SMS messages and assessments are available as supporting information; see S1 Screenshots and S1 Content.
To maximize similarity across conditions with respect to frequency of reporting on side effects and alcohol-related variables, as well as demand characteristics implicit in receiving a prepaid smartphone, participants in the control condition received a prepaid phone and received SASED prompts/assessments, but not adherence reminders/assessments.
Structured Clinical Interview for DSM-IV-TR (Baseline).
Sections covering diagnostic criteria for substance use disorders and psychosis were administered .
Alcohol Use Disorders Identification Test (AUDIT, Baseline).
The AUDIT  is a validated 10-item measure of alcohol involvement. Items are summed to create a score (ranging 0–40).
Alcohol Dependence Scale (ADS, Baseline).
The ADS  is a 25-item scale assessing alcohol dependence during the past 12 months. Items are summed to yield a quantitative index (ranging 0–47).
Penn Alcohol Craving Scale (PACS, Baseline).
The five items of the PACS  concern the frequency, intensity, and duration of thoughts about drinking; the ability to resist drinking; and average craving over the past week. Items were averaged to yield a score ranging 0–6. Part of the SASED, the craving intensity item ("At its most severe point, how strong was your craving to drink alcohol?") was re-administered daily, referring to the preceding day.
The Timeline Follow-back (TLFB) calendar method  was used to quantify alcohol use during the 90 days preceding Baseline and the 28 days preceding Weeks 4 and 8. As part of the SASED, drinking was queried daily via smartphone. Participants were asked how many standard drinks they consumed on the prior day, capped at 13 drinks.
Medication Event Monitoring System (MEMS, MWV Healthcare).
The MEMS is a system that integrates a small microcircuit into a lid for a medication vial, which records the time and date whenever the lid is opened. MEMS monitors are capable of storing up to 3800 medication events. According to the developers, over 700 peer-reviewed publications have used MEMS to compile drug dosing histories and assess compliance in patients in a wide variety of clinical situations (http://www.mwvaardex.com). Thus, MEMS is considered by many to be the "gold-standard" test of the reliability of medication-event monitoring. In the present study, participants received medication in a standard pill bottle with an electronic, chip-embedded MEMS cap that logged all openings. We attempted to retrieve MEMS caps from all randomized participants; however, some caps could not be retrieved. Raw MEMS adherence data were downloaded from 60 returned caps.
Sample Size Determination and Specification of Outcomes
As specified in the study protocol  our primary outcome was the proportion of participants with adequate adherence, defined as at least 80% of prescribed doses taken during the eight-week trial, as measured by MEMS. Details on the sample size determination can be found in the study protocol . In brief, a similar study by Simoni et al.  found a medium effect size for a pager intervention compared to a peer support intervention (w = .36) and compared to usual care (w = .32) using chi-square tests. Therefore, we anticipated a medium effect size for AGATE compared to SASED. Power analysis was conducted using G*Power 3 software [37,38]. For a χ² test with d.f. = 1 and α error probability set to. 05, a sample size of 88 yields power of. 80 to detect an effect size w = .30. Due to funding and time constraints, enrollment ended when the number of randomized participants reached 76.
Secondary outcomes were the continuous measures of adherence (i.e., percent of doses taken), latency to fall below 80% of cumulative doses taken, drinks per drinking day, craving intensity, latency to first drinking day (for those with an abstinence goal), and latency to first day of heavy drinking (≥4 [women] or ≥5 [men] standard drinks).
Preliminary analyses included T-tests and chi-square tests to examine whether 1) randomized participants differed from non-randomized participants in terms of demographics (age, gender, race, ethnicity, education level, or income); 2) Week 4 and Week 8 attendees differed from non-attendees in terms of demographics, drinking goal, AUDIT score, and ADS score; and 3) experimental conditions differed with regard to demographics, drinking goal, MEMS cap return, side effects, Week 4 and Week 8 attendance, and numbers of smartphone assessments completed. Indices of side effects included the proportion reporting any side effects in Days 1–7, 1–28, and 1–56, as well as a side effects score comprising the total number of side effects multiplied by number of days endorsed during each of these periods. Pearson's correlations were used to examine whether the indices of side effects were related to indices of adherence at mid-study or study end.
Given the once per day dosing schedule for naltrexone, MEMS data were cleaned to ensure that no more than one opening per day was counted as a taken dose. For each participant, the number of doses taken was expressed as a proportion of number of openings divided by number of days for Days 1–28 and Days 1–56. Each participant was then dichotomously coded as below or above our a priori 80% adherence threshold at mid-study and over the full 56 days.
The primary analysis examined the proportion of patients who were categorized as adherent (i.e., ≥80% of cumulative doses taken), All randomized participants were included in this analysis. If the MEMS cap was not returned, overall adherence was counted as zero. Secondary analyses examining continuous adherence data included both intention-to-treat (ITT) and per-protocol analyses. For ITT, overall adherence was computed for all randomized participants as a proportion of days on which an opening occurred from Day 1–56, unless the MEMS cap was not returned, in which case adherence was coded as 0%. Adherence was examined using analysis of covariance (ANCOVA) in the form of hierarchical multiple regression. Variables differing between groups at baseline were entered as covariates on the first step of hierarchical multiple regression analyses. R-square change was evaluated as experimental condition was entered into the regression equation on the second step of the hierarchical analysis. The per-protocol analyses focused on Week 4 outcomes for two reasons. First, participants who did not return for the Week 4 visit did not receive a refill and thus could not adhere for the full 56-day period. Second, the number of participants retained through Week 8 (n = 37) was substantially lower than the number required to detect a significant intervention effect on the primary outcome , reflecting high attrition. Given inadequate power to address the primary hypothesis with the Week 8 outcomes, unplanned per-protocol analyses examined mid-study adherence among those attending Week 4 whose MEMS caps were returned (n = 60), excluding 2 participants who had disclosed information invalidating their MEMS data (discarding pills, taking half- or double-doses).
Given that adherence tends to decline over time, analyses also examined whether the intervention helped participants maintain adequate adherence in the initial weeks of treatment. A secondary (unplanned) survival analysis examined latency to fall below 80% of cumulative doses taken. Daily cumulative adherence was defined as cumulative number of days with a bottle opening divided by cumulative number of days in the trial. Kaplan-Meier survival analysis evaluated whether experimental conditions differed in latency to fall below 80% adherence at midstudy and at study end.
To evaluate the association of adherence with relapse to heavy drinking, Kaplan-Meier survival analysis compared those above and below the adherence threshold at mid-study (80% doses taken, collapsed across experimental condition) with regard to two relapse variables derived from the Week 4 TLFB: latency to first drinking day (for those with an abstinence goal) and first day of heavy drinking (≥4 [women] or ≥5 [men] standard drinks).
Smartphone alcohol drinking and craving data were aggregated across Days 1–28 and 29–56 and compared using t-tests. All participants making at least one report during the 28-day period received a mean score for that period. SASED-derived mean drinks per drinking day during Days 1–28 and 29–56 were compared with TLFB-derived drinks per drinking day for the same periods using Pearson's correlations.
Table 1 presents baseline demographic and clinical characteristics of randomized participants. No differences were found between randomized and non-randomized individuals and between Week 4 attendees and non-attendees (study dropouts). Compared to Week 8 attendees, non-attendees (study dropouts and medical withdrawals/exclusions) were older (39.7 [SD = 8.9] vs. 35.5 [SD = 9.5] years, t = -2.00, p = .049) and more likely to be female (51.2% vs. 16.2%, χ² = 10.37, p = .001). Despite random assignment, the conditions differed with regard to gender, income, and ADS score; therefore, these variables were used as covariates. The experimental conditions did not differ on attendance, MEMS cap returns, or reported side effects.
Because our sample size of N = 76 fell short of our enrollment goal of 88 participants, we conducted a sensitivity analysis to determine the effect size that could be detected with a χ² test with d.f. = 1, α error probability set to. 05, and power of. 80. The analysis, conducted using G*Power 3 software [37,38], indicated that the detectable effect size with those parameters was w = .32, which was within the range observed by Simoni et al. .
Over Days 1–56, control participants averaged 39.2 [SD = 15.6] responses to SASED assessments. Intervention participants averaged 28.6 [SD = 16.0] SASED responses and 14.4 [SD = 7.5] AGATE-Rx responses for a total average of 42.9 [SD = 22.8]; therefore, the total number of responses did not differ between groups (t = -0.84, p = .404).
Side Effects and Adherence
Two thirds (67.1%) of participants reported side effects in the first week; one third (33.3%) reported anxiety, 22.7% reported nausea, 18.7% reported dizziness, 30.7% reported thirst, 37.3% reported sleep effects, and 20.0% reported weakness. By Day 28, 78.9% of participants had reported side effects. By study end, 80.3% had reported side effects. No index of side effects correlated significantly with adherence at mid-study or study end.
Adherence Outcomes by Condition
A chi-square test comparing groups in terms of the proportion of patients with adequate adherence (defined a priori as ≥ 80% of doses taken [13,16] was not significant at Week 4, χ² = 1.27, p = .260, or at Week 8, χ² = .91, p = .341. At Week 4, 48.6% of the experimental group and 35.9% of the control group were categorized as adequately adherent. These numbers assume 0% adherence for participants who did not return MEMS caps. At Week 8, 18.9% of the experimental group and 30.8% of the control group were categorized as adherent. As shown in Table 2, a secondary analysis examining adherence as a continuous outcome showed that experimental condition did not predict overall or mid-study adherence. Controlling for the covariates, mean overall adherence over 8 weeks was. 500 [95% CI = .381–.618] in the experimental group and. 453 [95% CI = .338–.568] in the control group. These means include zeros for 16 participants who did not return MEMS. Experimental condition also did not predict mid-study adherence in the per-protocol analysis including those whose MEMS caps were returned at Week 4. Controlling for covariates, mid-study adherence was. 828 [95% CI = .742–.915] in the experimental group and. 767 [95% CI = .680–.853] in the control group.
As illustrated in Fig 2, the secondary survival analysis revealed that the time to drop below 80% adherence was significantly different between experimental groups at midstudy (Mantel-Cox χ² = 4.28, p = .039) but not at study end (Mantel-Cox χ² = 0.46. p = .497). The median latency to fall below 80% cumulative adherence was 19 days [95% CI = 0.0–44.0] in the intervention group and 3 days [95% CI = 0.0–8.1] in the control group.
Time to first drop below 80% cumulative adherence among all randomized participants, time to first drink among participants with a goal of abstinence completing the Week 4 Timeline Followback assessment, and time to first heavy drinking episode among all participants completing the Week 4 Timeline Followback assessment.
Alcohol Use Outcomes by Condition
Fig 3 depicts 95% confidence intervals over time for drinks per drinking day and craving intensity, assessed via daily smartphone prompts. Across conditions, craving intensity decreased from Baseline [M = 3.8, SD = 1.5] through Days 1–28 [M = 2.0, SD = 1.3] (t = 9.2, p<.001) and 29–56 [M = 1.6, SD = 1.5] (t = 10.4, p<.001). The experimental conditions did not differ. Similarly, across conditions, drinks per drinking day decreased from Baseline [M = 10.0, SD = 5.7] through Days 1–28 [M = 4.9, SD = 1.8] (t = 7.4, p<.001) and 29–56 [M = 4.1, SD = 4.5] (t = 6.6, p<.001), with no difference between conditions. For comparison, mean drinks per drinking day derived from the TLFB were 2.8 [SD = 1.8] (Week 4) and 2.2 [SD = 1.4] (Week 8). Correlations between smartphone and TLFB measures of drinks per drinking day were. 430 (p = .001, n = 52) for Week 4/Days 1–28 and. 516 (p = .008, n = 25) for Week 8/Days 29–56.
95% confidence intervals around the mean numbers of self-reported drinks per drinking day (line graph) and ratings of alcohol craving intensity (column graph), assessed via smartphone, among heavy drinkers randomly assigned to the intervention or control condition. The number of participants making at least one report for each time frame is the number shown in the columns.
Drinking Outcomes Stratified by Adherence.
Fig 2 shows drinking outcomes stratified by midstudy adherence. Compared to those with <80% adherence (n = 29), those with ≥80% adherence (n = 31) did not significantly delay heavy drinking (Mantel-Cox χ² = 0.68. p = .408). Among those whose goal was to abstain, compared to those with <80% adherence (n = 18), those with ≥80% adherence (n = 15) did not significantly delay drinking (Mantel-Cox χ² = 2.11. p = .146).
This study is the first randomized, controlled trial to evaluate a mobile health (mHealth) intervention designed to improve adherence to pharmacotherapy in the treatment of alcohol use disorders. Results did not support the hypothesis that text message medication reminders and mobile web-based adherence assessment would improve adherence, above and beyond a control condition consisting of mobile assessment of side effects, drinking, and craving. Notably, high attrition resulted in an insufficient sample size at Week 8. In this context it was not surprising that ITT analyses (including all randomized individuals and assigning 0% adherence to those who discontinued) revealed no intervention effect and low overall estimates of adherence (50% cumulative through Week 8). A per-protocol analysis through Week 4 showed adherence rates of 83% (intervention group) and 77% (control group). These rates approach those reported in studies using psychosocial interventions to maximize adherence [14,15].
Secondary analyses suggested that the intervention group maintained adequate adherence (≥80% of doses taken) longer than the control group through Week 4, although the effect was not observed through Week 8. Therefore, one possibility is that mHealth approaches for monitoring adherence (or otherwise maintaining contact with participants) can support adequate short-term adherence in cases where psychosocial interventions are not available. Taken together, these findings suggest that a smartphone intervention involving daily assessment, without or without medication reminders, warrants further evaluation for maintaining adherence to pharmacotherapy among those engaged in treatment. The results further suggest that daily adherence reminders and assessments via smartphone may help sustain adherence during the first weeks of naltrexone treatment, when the incidence of relapse is generally highest. Contrary to other studies, adherence to naltrexone (defined as ≥80% of doses taken) was not associated with significantly longer latencies to first heavy drinking day (for all participants) or first drinking day (among those with an abstinence goal).
Advantages of the current study include the use of a novel technology designed specifically to support medication adherence during treatment for alcohol use disorders, and the use of MEMS to provide a relatively objective measure of adherence. While MEMS is a widely accepted measure of adherence, it indicates bottle openings rather than actual medication use; having a biomarker of adherence would increase confidence in pill adherence results. The comparison condition sought to control for the possibility that receiving a smartphone and/or using it to perform self-monitoring would exert an effect. The control condition was both a strength and a limitation, as it did not enable us to examine the effect of the intervention compared to treatment-as-usual (i.e., treatment without daily assessments via smartphone). The difference in attention (i.e., the number of text messages) between the conditions could be viewed as a limitation. Other limitations include the short 8-week treatment protocol and a relatively small sample size, in part reflecting the high number of study dropouts and discontinuations between Week 4 and Week 8. Attrition limited the statistical power and utility of the Week 8 assessments. Finally, while secondary analyses indicated that participants in the intervention condition maintained ≥80% adherence significantly longer than control participants, the clinical significance of this outcome has not been validated, and there was no association of medication adherence with drinking outcomes in the current sample.
This study offers preliminary support for the feasibility of mHealth interventions among treatment-seeking participants with alcohol use disorders. Participant engagement was relatively good in both conditions, with a number of smartphone assessments completed over the course of the study, which addresses concerns that individuals with alcohol dependence would be unlikely to complete mobile assessments . We expected that accountability for medication adherence via smartphone reminders and assessments improve adherence above and beyond daily alcohol use assessments; however, participants who were merely prompted to report on side effects, drinking, and craving had similar adherence rates as the intervention group, possibly through self-monitoring of the very targets of the medication: drinking and craving. It is important to acknowledge, however, that we did not have a reminder-without-assessment condition, which would be necessary to evaluate how mobile assessment per se compares to adherence reminders alone.
Evidence that remote monitoring of adherence and/or alcohol use improves treatment engagement would have implications for real-world treatment settings given the low cost of these interventions. All participants received smartphones with unlimited service to use in the study, costing approximately $300 USD per participant. We did not give participants an option to use their own smartphones so as to standardize and control the intervention experience. When such standardization and control are not concerns, intervention cost would be reduced as individuals across socioeconomic classes increasingly already have smartphones . Nonetheless, prepaid smartphones and service plans are decreasing in cost and may provide a more cost-effective than psychosocial interventions, which require in person attendance with a trained professional. mHealth interventions have additional advantages of requiring minimal staff time and enabling daily contact. Although not used in the current study, feedback loops can be incorporated to alert staff under predetermined conditions, for example, if certain side effects are reported or adherence has not been reported for a period of time.
In summary, the present findings support the feasibility of implementing a mHealth intervention for supporting adherence to pharmacotherapy among treatment-seeking participants; however, the current results did not support the efficacy of text message reminders on adherence, above and beyond remote assessments of drinking and craving. Despite these findings, trials with larger samples and alternate designs are warranted. In particular, given the use of a relatively rigorous control condition in the present study, future studies should compare mobile assessments and reminders to treatment-as-usual. Further questions include whether mHealth interventions can achieve adherence rates comparable to those achieved with psychosocial adherence interventions, or whether mHealth interventions could enhance effects of psychosocial interventions.
S1 Content. Study Smartphone Message and Assessment Content.
The authors thank the project staff and study participants and express appreciation to Dr. Kent Hutchison, Dr. Michael Bogenschutz, and Dr. Jane Simoni for their assistance with this project. Portions of these findings were presented at the 36th Annual Meeting of the Research Society on Alcoholism, July, 2013, Orlando, Florida.
Conceived and designed the experiments: SAS PBA CSH. Performed the experiments: SAS PBA CSH. Analyzed the data: SAS. Contributed reagents/materials/analysis tools: SAS PBA CSH. Wrote the paper: SAS PBA CSH.
- 1. Swift R, Oslin DW, Alexander M, Forman R. Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs 2011; 72: 1012–8. pmid:22051215
- 2. Reid SC, Teesson M, Sannibale C, Matsuda M, Haber PS. The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial. J Stud Alcohol 2005; 66: 833–41. pmid:16459945
- 3. Pettinati HM, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ. COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. DHHS Publication No. (NIH) 04–5289. Bethesda, MD: NIAAA; 2004. https://doi.org/10.1001/jama.2014.15939 pmid:25585329
- 4. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003–17. pmid:16670409
- 5. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol 2006; 26: 610–25. pmid:17110818
- 6. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010: CD001867.
- 7. Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S. Physicians' opinions about medications to treat alcoholism. Addiction 2003; 98: 617–26. pmid:12751979
- 8. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001; 25: 1634–47. pmid:11707638
- 9. Kranzler HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol 2000; 35: 537–47. pmid:11093959
- 10. Pettinati HM, Volpicelli JR, Pierce JD Jr, O'Brien CP. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 2000; 19: 71–83. pmid:11076121
- 11. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 1997; 54: 737–42. pmid:9283509
- 12. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000; 35: 587–93. pmid:11093966
- 13. Baros AM, Latham PK, Moak DH, Voronin K, Anton RF. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res 2007; 31: 596–603. pmid:17374038
- 14. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003; 6: 566–73. pmid:14627063
- 15. Oslin DW, Lynch KG, Pettinati HM, Kampman KM, Gariti P, Gelfand L, et al. A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res 2008; 32: 1299–308. pmid:18540910
- 16. Zweben A, Pettinati HM, Weiss RD, Youngblood M, Cox CE, Mattson ME, et al. Relationship between medication adherence and treatment outcomes: the COMBINE study. Alcohol Clin Exp Res 2008; 32: 1661–9. pmid:18616687
- 17. Rohsenow DJ, Colby SM, Monti PM, Swift RM, Martin RA, Mueller TI, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 2000; 24: 1542–9. pmid:11045863
- 18. Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med 2008; 359: 715–21. pmid:18703474
- 19. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 2000; 22: 493–503. pmid:10731624
- 20. Simoni JM, Huh D, Frick PA, Pearson CR, Andrasik MP, Dunbar PJ, et al. Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr 2009; 52: 465–73. pmid:19911481
- 21. Brown ES, Carmody TJ, Schmitz JM, Caetano R, Adinoff B, Swann AC, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res 2009; 33: 1863–9. pmid:19673746
- 22. Pettinati HM, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ. COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. DHHS Publication No. (NIH) 04–5289. Bethesda, MD: NIAAA; 2004. https://doi.org/10.1001/jama.2014.15939 pmid:25585329
- 23. Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP. Combining medication and psychosocial treatments for addictions: The BRENDA approach. New York: Guilford Press; 2001.
- 24. Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, et al. Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res 2004; 28: 1710–7. pmid:15547458
- 25. Gurvich EM, Kenna GA, Leggio L. Use of Novel Technology-Based Techniques to Improve Alcohol-Related Outcomes in Clinical Trials. Alcohol Alcohol 2013.
- 26. Linn AJ, Vervloet M, van Dijk L, Smit EG, Van Weert JC. Effects of eHealth interventions on medication adherence: a systematic review of the literature. J Med Internet Res 2011; 13: e103. pmid:22138112
- 27. Dimeff LA, Paves AP, Skutch JM, Woodcock EA. Shifting paradigms in clinical psychology: How innovative technologies are shaping treatment delivery. In: Barlow DH, editor. The Oxford Handbook of Clinical Psychology. New York: Oxford University Press; 2010. p. 618–48.
- 28. Heron KE, Smyth JM. Ecological momentary interventions: incorporating mobile technology into psychosocial and health behaviour treatments. Br J Health Psychol 2010; 15: 1–39. pmid:19646331
- 29. Dowshen N, Kuhns LM, Johnson A, Holoyda BJ, Garofalo R. Improving Adherence to Antiretroviral Therapy for Youth Living with HIV/AIDS: A Pilot Study Using Personalized, Interactive, Daily Text Message Reminders. J Med Internet Res 2012; 14: e51. pmid:22481246
- 30. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010; 376: 1838–45. pmid:21071074
- 31. Stoner SA, Hendershot CS. A randomized trial evaluating an mHealth system to monitor and enhance adherence to pharmacotherapy for alcohol use disorders. Addict Sci Clin Pract 2012; 7: 9. pmid:23186301
- 32. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
- 33. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption—II. Addiction 1993; 88: 791–804. pmid:8329970
- 34. Skinner HA, Allen BA. Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 1982; 91: 199–209. pmid:7096790
- 35. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 1999; 23: 1289–95. pmid:10470970
- 36. Sobell LC, Sobell MB. Timeline Followback: A technique for assessing self-reported ethanol consumption. In: Allen J, Litten RZ, editors. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press; 1992. p. 41–72.
- 37. Faul F, Erdfelder E, Buchner A, Lang A-G. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods 2007; 39: 175–91. pmid:17695343
- 38. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149–60. pmid:19897823
- 39. Rainie L. Internet, broadband, and cell phone statistics. Washington, DC: Pew Internet & American Life Project; 2009 [updated January 5, 2010; cited 2013 September 16, 2013]; Available: http://www.pewinternet.org/~/media//Files/Reports/2010/PIP_December09_update.pdf.